Could fewer heart tests be safer for breast cancer patients?
NCT ID NCT06930521
First seen Jun 12, 2026
Summary
This study looks at whether breast cancer patients on HER2-targeted therapy can safely have fewer heart tests. Currently, patients get heart scans every three months, but most don't change treatment. Researchers will test a personalized schedule based on heart risk, comparing it to the standard approach in 300 patients. The goal is to reduce stress, delays, and costs without compromising heart or cancer outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Toronto General Hospital
RECRUITINGToronto, Ontario, M5G 2C4, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a more personalized, less burdensome heart monitoring schedule for breast cancer patients, reducing unnecessary tests and healthcare costs.
What could go wrong
This is an early-stage study with only 300 participants, so results may not apply to all patients. There is a small risk that less frequent monitoring could miss early signs of heart damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.